Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 10.11.2021.

#drugdevelopment
#cellculture
#ai
#biotech
#vaccine
#covid19

Companies And Industries

@GENbio shared
On Nov 8, 2021
RT @GENBiotechJrnl: It is our pleasure to announce the appointment of the Editor-in-Chief of @GENBiotechJrnl, Dr. Hana El-Samad @HanaScientist, Kuo Family Endowed Professor and Vice Chair in the Department of Biochemistry and Biophysics @UCSF! https://t.co/bCnoevvfD9 1/ https://t.co/NegbaqFaiB
Open
Professor Hana El-Samad, PhD, Appointed Editor-in-Chief of GEN Biotechnology

Professor Hana El-Samad, PhD, Appointed Editor-in-Chief of GEN Biotechnology

News - Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in the most promising areas of ...

@FierceBiotech shared
On Nov 5, 2021
GlycoEra's origins are enough to make your head spin. The biotech spun off from LimmaTech, which itself spun out of a GlaxoSmithKline specialist vaccines unit known as GlycoVaxyn. https://t.co/1T3T8ojyg7
Open
Veterans from GSK's GlycoVaxyn rally up $49M to advance Swiss biotech GlycoEra

Veterans from GSK's GlycoVaxyn rally up $49M to advance Swiss biotech GlycoEra

Veronica Gambillara Fonck, Ph.D., has been one member of a group of scientists that have followed each other across a dizzying landscape of spinoffs and new ventures in vaccines R&D. Now, ...

@FiercePharma shared
On Nov 4, 2021
.@Moderna_tx has been biotech’s biggest growth story in 2021, but the company’s rate of expansion has slowed. https://t.co/kPZAKrNhTp
Open
Shipping delays, supply chain expansions ding Moderna's COVID-19 vaccine business

Shipping delays, supply chain expansions ding Moderna's COVID-19 vaccine business

Moderna has been biotech’s biggest growth story in 2021, but the company’s rate of expansion slowed considerably in recent months as shipping delays on its COVID-19 vaccine and a supply ...

@FierceBiotech shared
On Nov 8, 2021
Teplizumab remains a priority, but the addition of Sanjuan, who has had stints and Bristol Myers Squibb and Medimmune, also helps more sharply focus the biotech’s work on earlier assets https://t.co/tbM7gRvxUZ
Open
Provention Bio, hit by AdComm rejection for lead drug, hires early research exec from Gossamer

Provention Bio, hit by AdComm rejection for lead drug, hires early research exec from Gossamer

Provention Bio has come out with a little bit of good news amid a tough 2021 as it hires former Gossamer Bio early R&D lead Miguel Sanjuan, Ph.D., to help shore up its early shots on goal.

@OGConferences shared
On Nov 9, 2021
Join our Free 3D Cell Culture Online Symposium. Our congress encompasses presentations on innovative technologies in 3D modelling and the acceleration of #drugdevelopment through the integration of 3D #cellculture. Free Passes for Industry/Academic 👉 https://t.co/TBHiVi7QAf https://t.co/iwID6SPYSS
Open
3D Cell Culture Symposium

3D Cell Culture Symposium

3D Cell CultureSymposium02 December 2021 | Online: GMT (UTC+0) Our 3D Cell Culture symposium incorporates key trends and innovative technologies to accelerate the adoption of 3D models in ...

@biospace shared
On Nov 10, 2021
New company enters AI space with $40 million in hand #ai #biotech https://t.co/RFplvuSMiV
Open
New Company Enters AI Space with $40 Million in Hand

New Company Enters AI Space with $40 Million in Hand

DeepCure announced the closing of its $40 million Series A financing round. The round, led by Morningside Ventures, brings the company’s total amount raised to $47 million since it was ...

@biospace shared
On Nov 4, 2021
COVID-19 update: UK approves Molnupiravir, WHO authorizes Ocugen/Bharat vaccine #covid19 #vaccine https://t.co/PYEGRj9Igu
Open
COVID-19 Update: UK Approves Molnupiravir, WHO Authorizes Ocugen/Bharat Vaccine

COVID-19 Update: UK Approves Molnupiravir, WHO Authorizes Ocugen/Bharat Vaccine

Merck and Ridgeback Biotherapeutics’ antiviral drug molnupiravir, which showed great promise against COVID-19 in clinical trials, received its first authorization.

@FierceBiotech shared
On Nov 10, 2021
“The IND clearance [in August] and the start-up of the phase 1 clinical trial mark the beginning of the Company's strategic shift toward focusing on P-BCMA-ALLO1 rather than the autologous P-BCMA-101 program" https://t.co/SdTp5SbnIV
Open
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf

Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf

The future of cell therapy is allogenic, it seems, as Poseida has decided to back away from work on its autologous candidate.

Read more: Companies And Industries
weekly 10.11.2021
View archives
Back to home

Subscribe to Biotech Essentials - Companies & Industries.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech Essentials - Companies & Industries.
Privacy Policy

Sign up for the weekly Biotech Essentials - Companies & Industries newsletter

Never again miss anything or anyone that matter in Biotech Essentials

Sign up and receive the Biotech Essentials - Companies & Industries weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy